Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.5K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.5K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

861
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
861
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.5K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.0K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

854
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
854
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

974
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
974

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report.

The Journal of clinical psychiatry·2023
Same author

Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia.

Psychiatry research·2023
Same author

Influence of <i>CYP2C19</i>, <i>CYP2D6</i>, and <i>ABCB1</i> Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2023
Same author

The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review.

Psychological medicine·2023
Same author

Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication.

JAMA network open·2023
Same author

Author Correction: Highly specific and non-invasive imaging of Piezo1-dependent activity across scales using GenEPi.

Nature communications·2023

Related Experiment Video

Updated: Jan 27, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.5K

Editorial: treatment with antidepressants

Hubertus Himmerich, Daniel J Müller

    Current Pharmaceutical Design
    |June 12, 2012
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
    11:39

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

    Published on: July 11, 2013

    39.5K
    The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
    10:29

    The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

    Published on: November 12, 2010

    40.5K

    Related Experiment Videos

    Last Updated: Jan 27, 2026

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
    04:29

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

    Published on: January 7, 2019

    29.5K
    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
    11:39

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

    Published on: July 11, 2013

    39.5K
    The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
    10:29

    The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

    Published on: November 12, 2010

    40.5K